On October 14, 2026, Sono-Tek Corporation filed an 8-K with the SEC, detailing its financial results for the second quarter and first half of fiscal year 2027. This filing is significant for investors and stakeholders as it provides insights into the company's performance and future outlook.

Background

Founded in New York, Sono-Tek Corporation (CIK: 0000806172) specializes in developing and manufacturing precision ultrasonic coating systems. The company is listed on NASDAQ under the symbol SOTK. An 8-K filing is used by publicly traded companies to report major events that shareholders should know about, including financial results, acquisitions, or changes in management.

What the Filing Says

The filing includes several key highlights from Sono-Tek's financial performance:

  • Net sales for the second quarter increased 1% to $5.23 million compared to $5.16 million in the same quarter last year.
  • Gross profit rose by 7% to $2.77 million, with a gross margin of 53%.
  • Operating income was reported at $382,000, down from $421,000 in the prior-year period.
  • Net income for the quarter was $366,000, or $0.02 per diluted share, compared to $424,000, or $0.03 per diluted share, a year earlier.
  • Medical market sales surged 209% to $3.11 million, driven by strong demand for balloon coating and specialty stent-coating systems.

For the first half of fiscal 2027, Sono-Tek reported:

  • Net sales increased by 6% to $10.89 million.
  • Gross profit grew by 14% to $5.98 million, with a gross margin of 55%.
  • Operating income rose 41% to $1.28 million.
  • Net income increased 22% to $1.11 million.
  • Medical market sales jumped 289% to $7.05 million.

Additionally, the company noted that it has a cash position of $17.7 million and a backlog of $9.51 million as of August 31, 2026. Sono-Tek also received three new orders totaling approximately $7.19 million, expected to ship in fiscal 2028, which enhances revenue visibility.

Impact

This filing may affect various stakeholders, including investors, analysts, and employees. Investors will be particularly interested in the company's growth in the medical sector, which has shown significant promise. Analysts may adjust their forecasts based on the reported financial results and the company's guidance for modest revenue growth moving forward. Employees may also feel a sense of job security given the company's reported growth and backlog.

What's Next

The filing does not say what happens next. However, the company has reiterated its expectation for flat to modest revenue growth for the full fiscal year 2027, reflecting the timing of several large orders.